South Korea
· Delayed Price · Currency is KRW CG MedTech Statistics
Total Valuation
CG MedTech has a market cap or net worth of KRW 95.72 billion. The enterprise value is 67.35 billion.
| Market Cap | 95.72B |
| Enterprise Value | 67.35B |
Important Dates
The next estimated earnings date is Thursday, August 14, 2025.
| Earnings Date | Aug 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CG MedTech has 103.26 million shares outstanding. The number of shares has increased by 22.48% in one year.
| Current Share Class | 103.26M |
| Shares Outstanding | 103.26M |
| Shares Change (YoY) | +22.48% |
| Shares Change (QoQ) | -36.11% |
| Owned by Insiders (%) | 0.42% |
| Owned by Institutions (%) | n/a |
| Float | 46.81M |
Valuation Ratios
The trailing PE ratio is 60.43.
| PE Ratio | 60.43 |
| Forward PE | n/a |
| PS Ratio | 2.52 |
| PB Ratio | 1.10 |
| P/TBV Ratio | 1.16 |
| P/FCF Ratio | 98.33 |
| P/OCF Ratio | 32.54 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 28.55, with an EV/FCF ratio of 69.19.
| EV / Earnings | 44.58 |
| EV / Sales | 1.77 |
| EV / EBITDA | 28.55 |
| EV / EBIT | 102.59 |
| EV / FCF | 69.19 |
Financial Position
The company has a current ratio of 4.69, with a Debt / Equity ratio of 0.04.
| Current Ratio | 4.69 |
| Quick Ratio | 3.36 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | 1.58 |
| Debt / FCF | 3.82 |
| Interest Coverage | 3.45 |
Financial Efficiency
Return on equity (ROE) is 1.78% and return on invested capital (ROIC) is 0.49%.
| Return on Equity (ROE) | 1.78% |
| Return on Assets (ROA) | 0.42% |
| Return on Invested Capital (ROIC) | 0.49% |
| Return on Capital Employed (ROCE) | 0.67% |
| Revenue Per Employee | 362.19M |
| Profits Per Employee | 14.39M |
| Employee Count | 105 |
| Asset Turnover | 0.39 |
| Inventory Turnover | 1.85 |
Taxes
In the past 12 months, CG MedTech has paid 207.87 million in taxes.
| Income Tax | 207.87M |
| Effective Tax Rate | 12.96% |
Stock Price Statistics
The stock price has decreased by -41.26% in the last 52 weeks. The beta is -0.62, so CG MedTech's price volatility has been lower than the market average.
| Beta (5Y) | -0.62 |
| 52-Week Price Change | -41.26% |
| 50-Day Moving Average | 958.90 |
| 200-Day Moving Average | 1,088.44 |
| Relative Strength Index (RSI) | 37.02 |
| Average Volume (20 Days) | 297,610 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, CG MedTech had revenue of KRW 38.03 billion and earned 1.51 billion in profits. Earnings per share was 15.34.
| Revenue | 38.03B |
| Gross Profit | 16.84B |
| Operating Income | 640.78M |
| Pretax Income | 1.60B |
| Net Income | 1.51B |
| EBITDA | 2.34B |
| EBIT | 640.78M |
| Earnings Per Share (EPS) | 15.34 |
Balance Sheet
The company has 32.23 billion in cash and 3.71 billion in debt, giving a net cash position of 28.51 billion or 276.13 per share.
| Cash & Cash Equivalents | 32.23B |
| Total Debt | 3.71B |
| Net Cash | 28.51B |
| Net Cash Per Share | 276.13 |
| Equity (Book Value) | 87.27B |
| Book Value Per Share | 843.75 |
| Working Capital | 41.48B |
Cash Flow
In the last 12 months, operating cash flow was 2.94 billion and capital expenditures -1.97 billion, giving a free cash flow of 973.51 million.
| Operating Cash Flow | 2.94B |
| Capital Expenditures | -1.97B |
| Free Cash Flow | 973.51M |
| FCF Per Share | 9.43 |
Margins
Gross margin is 44.29%, with operating and profit margins of 1.68% and 3.97%.
| Gross Margin | 44.29% |
| Operating Margin | 1.68% |
| Pretax Margin | 4.22% |
| Profit Margin | 3.97% |
| EBITDA Margin | 6.16% |
| EBIT Margin | 1.68% |
| FCF Margin | 2.56% |
Dividends & Yields
CG MedTech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -22.48% |
| Shareholder Yield | n/a |
| Earnings Yield | 1.58% |
| FCF Yield | 1.02% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on August 5, 2022. It was a forward split with a ratio of 5.
| Last Split Date | Aug 5, 2022 |
| Split Type | Forward |
| Split Ratio | 5 |
Scores
CG MedTech has an Altman Z-Score of 3.83 and a Piotroski F-Score of 4.
| Altman Z-Score | 3.83 |
| Piotroski F-Score | 4 |